{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:20Z","timestamp":1740144200950,"version":"3.37.3"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","funder":[{"DOI":"10.13039\/501100009579","name":"Health Department of Sichuan Province","doi-asserted-by":"crossref","award":["YLZLZ1801"],"award-info":[{"award-number":["YLZLZ1801"]}],"id":[{"id":"10.13039\/501100009579","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1097\/md.0000000000022566","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T20:55:44Z","timestamp":1605041744000},"page":"e22566","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of evocalcet in treatment of secondary hyperparathyroidism in chronic kidney disease on hemodialysis patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Jing","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"R1-20230103","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000156717","article-title":"Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"29","author":"Shigematsu","year":"2009","journal-title":"Am J Nephrol"},{"key":"R2-20230103","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrneph.2013.147","article-title":"FGF-23 and secondary hyperparathyroidism in chronic kidney disease","volume":"9","author":"Silver","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"R3-20230103","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R4-20230103","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ki.2015.72","article-title":"Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"88","author":"Komaba","year":"2015","journal-title":"Kidney Int"},{"key":"R5-20230103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncpneph0977","article-title":"Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?","volume":"5","author":"Wetmore","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"key":"R6-20230103","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1681\/ASN.V1161141","article-title":"Cell biology of parathyroid gland hyperplasia in chronic renal failure","volume":"11","author":"Drueke","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"(5 Suppl)","key":"R7-20230103","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0272-6386(03)00371-8","article-title":"Meeting the challenges of the new K\/DOQI guidelines","volume":"41","author":"Eknoyan","year":"2003","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"R8-20230103","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/sdi.12357","article-title":"The use of calcimimetics for the treatment of secondary hyperparathyroidism: a 10 year evidence review","volume":"28","author":"Rodriguez","year":"2015","journal-title":"Semin Dial"},{"key":"R9-20230103","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","article-title":"Calcimimetics with potent and selective activity on the parathyroid calcium receptor","volume":"95","author":"Nemeth","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-20230103","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/ckj\/sfx125","article-title":"Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes","volume":"11","author":"Pereira","year":"2018","journal-title":"Clin Kidney J"},{"key":"R11-20230103","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"R12-20230103","first-page":"567","article-title":"Parenteral calcimimetics for the treatment of secondary hyperparathyroidism","volume":"27","author":"Hamano","year":"2017","journal-title":"Clin Calcium"},{"key":"R13-20230103","article-title":"Evocalcet: a new oral calcimimetic for dialysis patients with secondary hyperparathyroidism","author":"Akizawa","year":"2019","journal-title":"Ther Apher Dial"},{"key":"R14-20230103","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40261-018-0687-4","article-title":"Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: first-in-human phase I study","volume":"38","author":"Akizawa","year":"2018","journal-title":"Clin Drug Investig"},{"key":"R15-20230103","doi-asserted-by":"crossref","first-page":"e0195316","DOI":"10.1371\/journal.pone.0195316","article-title":"A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro","volume":"13","author":"Kawata","year":"2018","journal-title":"PLoS One"},{"key":"R16-20230103","first-page":"101","article-title":"Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan","volume":"10","author":"Shigematsu","year":"2018","journal-title":"Clin Pharmacol"},{"key":"R17-20230103","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s10157-018-1635-6","article-title":"Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients","volume":"23","author":"Shigematsu","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"R18-20230103","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10157-019-01692-y","article-title":"Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients","volume":"23","author":"Tsuruya","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"R19-20230103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1254\/fpj.154.35","article-title":"Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA((R)))","volume":"154","author":"Tokunaga","year":"2019","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"R20-20230103","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","article-title":"Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"Fukagawa","year":"2018","journal-title":"Kidney Int"},{"key":"R21-20230103","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1038\/s41598-019-42017-z","article-title":"Long-Term efficacy and safety of evocalcet in Japanese patients with secondary hyperparathyroidism receiving hemodialysis","volume":"9","author":"Yokoyama","year":"2019","journal-title":"Sci Rep"},{"key":"R22-20230103","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2020.02.439","article-title":"Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis","author":"Palmer","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"R23-20230103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R24-20230103","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R26-20230103","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R27-20230103","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R28-20230103","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence--inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R29-20230103","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Investigators","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T16:14:39Z","timestamp":1672762479000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022566"}},"subtitle":["A protocol for a systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":28,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022566","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,11,13]]}}}